Anti-LAG-3 antibodies and methods of use thereof

Inventors

Wilson, Nicholas Stuart • Savitsky, David Adam • Jennings, Shawn Michael • van Dijk, Marc • Mundt, Cornelia Anne

Assignees

Agenus Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-12187795-B2

Patent

Publication Date

2025-01-07

Expiration Date


Abstract

The instant disclosure provides antibodies that specifically bind to LAG-3 (e.g., human LAG-3) and antagonize LAG-3 function. Also provided are pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Core Innovation

The patent discloses anti-LAG-3 antibodies that bind human LAG-3 and antagonize LAG-3-mediated immune suppression or LAG-3 function. The antibodies are defined by specified CDRH1, CDRH2, CDRH3 and CDRL1, CDRL2, CDRL3 patterns, with heavy and light chain variable regions referenced by sequence identifiers and, in some embodiments, humanized variable-region variants and framework-region sources.

The disclosure further includes framework-region substitutions using Kabat and Rabat numbering, together with enumerated framework substitutions. It also describes constant-region embodiments including selected Ig classes or subclasses, Fc mutations, afucosylated IgG1 embodiments, pyroglutamate N-terminal residues, aglycosylated antibodies, and other constant-region variant selections.

The subject matter further includes polynucleotides, expression vectors, recombinant host cells, and pharmaceutical compositions for therapeutic use. It also describes combination regimens with immune checkpoint agents, IDO/TDO inhibitors, chemotherapeutics/radiotherapeutics, vaccines/adjuvants, and engineered immune cell approaches, as well as diagnostic, prognostic, and monitoring uses through immunoassays and immunohistochemistry.

Claims Coverage

The provided independent claims define three inventive features: isolated polynucleotides encoding antibodies with specified CDR regions in defined VH/VL sequence contexts, isolated polynucleotides with human framework-region sources and selected substitutions, and a method for producing an antibody that binds human LAG-3 by expressing a specified polynucleotide in a host cell.

Isolated polynucleotide encoding an antibody with specified CDRs in defined VH/VL sequences

An isolated polynucleotide encoding an antibody comprising complementarity determining regions CDRH1, CDRH2, CDRH3, CDRL1, CDRL2 and CDRL3, wherein the heavy and light chain variable regions are defined by specified SEQ ID NOs.

Isolated polynucleotide with human framework-region sources and selected substitutions

An isolated polynucleotide whose encoded antibody includes specified human-derived heavy and light chain variable framework regions, optionally with listed framework-region substitutions and related SEQ ID constraints.

Method for producing an antibody that binds to human LAG-3 by expressing a specified polynucleotide in a host cell

A method for producing an antibody that binds to human LAG-3 by culturing a host cell so that a specified polynucleotide is expressed and the antibody is produced.

Overall, the claim coverage centers on isolated polynucleotides encoding antibodies with specified CDR regions in defined VH/VL sequence contexts, optionally further specified by human framework-region sources and substitutions, and an expression-based production method in a host cell that yields an antibody binding human LAG-3.

Stated Advantages

Antagonizes LAG-3-mediated immune suppression.

Increases T-cell activation.

Supports blockade or inhibition of LAG-3 function as reflected in binding and functional immune readouts.

Affects ligand binding to MHC class II.

Decreases or modulates cytokine production including IL-2 production and TNFα production.

Enables treatment of cancer.

Enables treatment of infectious diseases.

Supports combination therapy with checkpoint therapies including PD-1/PD-L1/CTLA-4.

Supports combination therapy with IDO inhibitors.

Documented Applications

Pharmaceutical compositions for treating cancer.

Pharmaceutical compositions for treating infectious diseases.

Combination therapy with checkpoint therapies including PD-1/PD-L1/CTLA-4.

Combination therapy with IDO inhibitors.

In vivo pharmaceutical use of anti-LAG-3 antibodies, including tissue/tumor targeting and sterile administration.

Treatment of cancer.

Treatment of infectious diseases including viral, bacterial, fungal, protozoal, and parasitic diseases.

Treatment of nervous system disorders, including Parkinson’s disease.

Use in combination regimens with immune checkpoint agents including anti-PD-1, anti-PD-L1, anti-CTLA-4, and other checkpoints.

Use in combination regimens with IDO/TDO inhibitors including epacadostat and other inhibitors.

Use in combination regimens with chemotherapeutics/radiotherapeutics.

Use in combination regimens with vaccines/adjuvants including peptide/DNA/RNA and HSP-based tumor/pathogen vaccines and adjuvants such as QS-21 STIMULON, CFA/IFA, and alum.

Use with engineered immune cell approaches including TCRs, CAR-T, and TCR-mimic antibodies.

Antibody diagnostic, prognostic, and monitoring uses via immunoassays and immunohistochemistry.

Therapeutic co-administration with additional agents, including checkpoint inhibitors such as anti-PD-1, anti-PD-L1 and anti-CTLA-4, and other listed immuno-oncology targets.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.